{"title":"印度中部参考实验室结核杆菌的耐药性趋势:向消灭结核病迈进。","authors":"Prabha Desikan , Nikita Panwalkar , Aseem Rangnekar , Zeba Khan , Ram Prakash Punde , Arun Kumar Sharma , Ragini Kushwaha , Chinnaiyan Ponnuraja , Sridhar Anand","doi":"10.1016/j.ijmmb.2024.100701","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.</p></div><div><h3>Methods</h3><p>A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. <em>Mycobacterium tuberculosis</em> (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.</p></div><div><h3>Results</h3><p>A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.</p></div><div><h3>Conclusion</h3><p>The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100701"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination\",\"authors\":\"Prabha Desikan , Nikita Panwalkar , Aseem Rangnekar , Zeba Khan , Ram Prakash Punde , Arun Kumar Sharma , Ragini Kushwaha , Chinnaiyan Ponnuraja , Sridhar Anand\",\"doi\":\"10.1016/j.ijmmb.2024.100701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><p>The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.</p></div><div><h3>Methods</h3><p>A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. <em>Mycobacterium tuberculosis</em> (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.</p></div><div><h3>Results</h3><p>A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.</p></div><div><h3>Conclusion</h3><p>The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.</p></div>\",\"PeriodicalId\":13284,\"journal\":{\"name\":\"Indian Journal of Medical Microbiology\",\"volume\":\"51 \",\"pages\":\"Article 100701\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0255085724001762\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085724001762","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination
Purpose
The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.
Methods
A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. Mycobacterium tuberculosis (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.
Results
A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.
Conclusion
The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.
期刊介绍:
Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study.
Review articles, Special Articles or Guest Editorials are accepted on invitation.